DV
Dividend Vision

SEPN — Septerna, Inc. Common Stock

Septerna, Inc. Common Stock (SEPN)

Total return is 147.2% over the past 1.8 years, 110.4 points ahead of SPY at 36.8%. Its deepest 1-year drawdown was 25.2%.

Septerna is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs targeting G protein-coupled receptors (GPCRs) for endocrinology, immunology, inflammation, and metabolic diseases, with programs in development for conditions including hypoparathyroidism, chronic spontaneous urticaria, and Graves' disease. The company does not currently distribute dividends. Septerna appeals to investors seeking exposure to early-stage biotech development rather than current income generation.

SEPN key facts

Asset type
Stock
Asset class
Equity
Inception date
10/24/2024
Last close
$44.50
Market cap
$1,451,882,880
Average volume
630400.0
Payout ratio
0.0
Forward P/E
107.5269
EPS
$-0.77